Cetuximab

Generic Name
Cetuximab
Brand Names
Erbitux
Drug Type
Biotech
Chemical Formula
-
CAS Number
205923-56-4
Unique Ingredient Identifier
PQX0D8J21J
Background

Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...

Indication

Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...

Associated Conditions
Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate the Safety and Efficacy of KQB365 As Monotherapy and in Combination in Participants with Advanced Solid Malignancies

First Posted Date
2024-12-06
Last Posted Date
2024-12-06
Lead Sponsor
Kumquat Biosciences Inc.
Target Recruit Count
128
Registration Number
NCT06720987

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

First Posted Date
2024-11-26
Last Posted Date
2024-11-26
Lead Sponsor
Centre Leon Berard
Target Recruit Count
460
Registration Number
NCT06706401
Locations
🇫🇷

Centre Léon Bérard, Lyon, France

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

First Posted Date
2024-10-29
Last Posted Date
2024-12-18
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
1000
Registration Number
NCT06662786
Locations
🇲🇾

Hospital Pulau Pinang, Georgetown, Malaysia

🇲🇾

Hospital Umum Sarawak, Kuching, Malaysia

🇲🇾

Hospital Raja Permaisuri Bainun, Ipoh, Malaysia

and more 20 locations

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Target Recruit Count
355
Registration Number
NCT06647563

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

First Posted Date
2024-09-23
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
750
Registration Number
NCT06607185
Locations
🇨🇳

Hsin-Chu Hospital, Hsin-chu, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 21 locations

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

First Posted Date
2024-09-19
Last Posted Date
2024-10-30
Lead Sponsor
AstraZeneca
Target Recruit Count
430
Registration Number
NCT06599502
Locations
🇹🇷

Research Site, Istanbul, Turkey

A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

First Posted Date
2024-09-19
Last Posted Date
2024-11-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
530
Registration Number
NCT06586515
Locations
🇺🇸

UCLA, Santa Monica, California, United States

🇺🇸

City of Hope Medical Group, South Pasadena, California, United States

🇺🇸

Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States

and more 40 locations

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

First Posted Date
2024-09-19
Last Posted Date
2024-12-20
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
158
Registration Number
NCT06589804
Locations
🇺🇸

Benefis Sletten Cancer Institute, Great Falls, Montana, United States

🇺🇸

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States

🇺🇸

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States

and more 15 locations

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

First Posted Date
2024-09-05
Last Posted Date
2024-12-13
Lead Sponsor
BeiGene
Target Recruit Count
177
Registration Number
NCT06585488
Locations
🇺🇸

Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States

🇺🇸

University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States

🇺🇸

Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States

and more 12 locations

Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Phase 2
Recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Cetuximab
Drug: Encorafenib
First Posted Date
2024-08-29
Last Posted Date
2024-11-22
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
16
Registration Number
NCT06578559
Locations
🇮🇹

Pia Fondazione di Culto e di Religione Cardinale G. Panico, Tricase, LE, Italy

🇮🇹

Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst, Meldola, FC, Italy

🇮🇹

Fondazione Casa Sollievo Della Sofferenza - Irccs, San Giovanni Rotondo, FG, Italy

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy